Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 146 | 2024 | 5302 | 12.530 |
Why?
|
Receptor Protein-Tyrosine Kinases | 68 | 2023 | 1624 | 10.740 |
Why?
|
Lung Neoplasms | 180 | 2024 | 13337 | 10.530 |
Why?
|
Protein Kinase Inhibitors | 101 | 2024 | 5665 | 7.870 |
Why?
|
Pyrazoles | 71 | 2024 | 2007 | 7.350 |
Why?
|
Lactams, Macrocyclic | 27 | 2024 | 318 | 6.760 |
Why?
|
Protein-Tyrosine Kinases | 33 | 2023 | 2423 | 5.510 |
Why?
|
Pyridines | 51 | 2022 | 2875 | 5.450 |
Why?
|
Carbazoles | 18 | 2022 | 220 | 4.890 |
Why?
|
Drug Resistance, Neoplasm | 50 | 2024 | 5305 | 4.200 |
Why?
|
Proto-Oncogene Proteins | 31 | 2021 | 4510 | 4.170 |
Why?
|
Gene Rearrangement | 28 | 2019 | 1125 | 4.060 |
Why?
|
Sulfones | 17 | 2021 | 447 | 3.550 |
Why?
|
Piperidines | 19 | 2021 | 1656 | 3.030 |
Why?
|
Antineoplastic Agents | 49 | 2023 | 13637 | 2.700 |
Why?
|
Lactams | 22 | 2024 | 156 | 2.610 |
Why?
|
Oncogene Proteins, Fusion | 19 | 2021 | 1606 | 2.280 |
Why?
|
Pyrimidines | 24 | 2021 | 3027 | 2.190 |
Why?
|
Aminopyridines | 23 | 2024 | 573 | 2.130 |
Why?
|
Mutation | 59 | 2024 | 30045 | 1.360 |
Why?
|
Brain Neoplasms | 18 | 2022 | 9031 | 1.350 |
Why?
|
Proto-Oncogene Proteins c-ret | 5 | 2018 | 225 | 1.130 |
Why?
|
Translocation, Genetic | 6 | 2016 | 1393 | 0.910 |
Why?
|
Indazoles | 5 | 2019 | 304 | 0.910 |
Why?
|
Taxoids | 6 | 2017 | 667 | 0.840 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 17 | 2021 | 11740 | 0.840 |
Why?
|
Adenocarcinoma | 12 | 2018 | 6339 | 0.830 |
Why?
|
ras Proteins | 7 | 2015 | 1053 | 0.820 |
Why?
|
Humans | 202 | 2024 | 761423 | 0.750 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 11 | 2020 | 1743 | 0.740 |
Why?
|
Benzamides | 6 | 2021 | 1370 | 0.720 |
Why?
|
Genes, erbB-1 | 2 | 2017 | 162 | 0.620 |
Why?
|
Platinum | 1 | 2019 | 220 | 0.610 |
Why?
|
Receptor, trkA | 4 | 2020 | 159 | 0.590 |
Why?
|
Molecular Targeted Therapy | 16 | 2023 | 2811 | 0.590 |
Why?
|
In Situ Hybridization, Fluorescence | 11 | 2020 | 2510 | 0.590 |
Why?
|
Genetic Heterogeneity | 3 | 2017 | 732 | 0.580 |
Why?
|
Drug Resistance | 2 | 2013 | 1595 | 0.570 |
Why?
|
Prognosis | 27 | 2022 | 29620 | 0.560 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2019 | 2054 | 0.550 |
Why?
|
Middle Aged | 85 | 2024 | 220826 | 0.540 |
Why?
|
Aged | 73 | 2024 | 169235 | 0.520 |
Why?
|
Adult | 77 | 2024 | 221148 | 0.500 |
Why?
|
Organophosphorus Compounds | 4 | 2018 | 206 | 0.490 |
Why?
|
Proto-Oncogene Proteins c-met | 7 | 2021 | 570 | 0.490 |
Why?
|
Anilides | 3 | 2022 | 411 | 0.490 |
Why?
|
Neoplasms | 12 | 2020 | 22164 | 0.480 |
Why?
|
Genomic Instability | 2 | 2023 | 709 | 0.470 |
Why?
|
Female | 101 | 2024 | 392581 | 0.470 |
Why?
|
Guanine | 2 | 2013 | 279 | 0.470 |
Why?
|
Glutamates | 2 | 2013 | 389 | 0.470 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 258 | 0.450 |
Why?
|
Male | 93 | 2024 | 360736 | 0.440 |
Why?
|
Puerperal Disorders | 1 | 2016 | 299 | 0.430 |
Why?
|
Meningeal Carcinomatosis | 1 | 2013 | 63 | 0.430 |
Why?
|
Clinical Trials, Phase I as Topic | 5 | 2019 | 326 | 0.420 |
Why?
|
Disease-Free Survival | 12 | 2017 | 6814 | 0.420 |
Why?
|
HSP90 Heat-Shock Proteins | 4 | 2018 | 424 | 0.410 |
Why?
|
Aged, 80 and over | 40 | 2021 | 58956 | 0.400 |
Why?
|
Cell Line, Tumor | 20 | 2021 | 16979 | 0.390 |
Why?
|
Bone Neoplasms | 2 | 2022 | 2529 | 0.370 |
Why?
|
Genes, ras | 4 | 2009 | 654 | 0.360 |
Why?
|
Immunotherapy | 7 | 2018 | 4650 | 0.350 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2019 | 10766 | 0.340 |
Why?
|
Survival Rate | 9 | 2019 | 12720 | 0.330 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2013 | 487 | 0.330 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2013 | 1171 | 0.320 |
Why?
|
Central Nervous System Neoplasms | 4 | 2017 | 916 | 0.310 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2019 | 422 | 0.310 |
Why?
|
Treatment Outcome | 27 | 2019 | 64651 | 0.310 |
Why?
|
Loss of Heterozygosity | 1 | 2010 | 662 | 0.310 |
Why?
|
Acrylamides | 4 | 2018 | 259 | 0.310 |
Why?
|
Kaplan-Meier Estimate | 11 | 2018 | 6479 | 0.290 |
Why?
|
Young Adult | 26 | 2021 | 59207 | 0.290 |
Why?
|
Tumor Burden | 5 | 2020 | 1890 | 0.280 |
Why?
|
Spinal Neoplasms | 1 | 2013 | 716 | 0.280 |
Why?
|
Gene Fusion | 2 | 2019 | 356 | 0.280 |
Why?
|
Maximum Tolerated Dose | 4 | 2020 | 883 | 0.280 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2021 | 8545 | 0.270 |
Why?
|
Hypogonadism | 1 | 2012 | 798 | 0.260 |
Why?
|
Retrospective Studies | 26 | 2022 | 80582 | 0.260 |
Why?
|
Drug Hypersensitivity | 1 | 2014 | 917 | 0.250 |
Why?
|
Clinical Trials as Topic | 9 | 2020 | 8000 | 0.250 |
Why?
|
Meningeal Neoplasms | 1 | 2015 | 1248 | 0.250 |
Why?
|
Survival Analysis | 6 | 2020 | 10089 | 0.250 |
Why?
|
Quinazolines | 4 | 2018 | 1371 | 0.250 |
Why?
|
Neoplasm Staging | 12 | 2020 | 11106 | 0.250 |
Why?
|
Biopsy | 8 | 2021 | 6766 | 0.250 |
Why?
|
Patient Selection | 4 | 2020 | 4244 | 0.250 |
Why?
|
DNA Mutational Analysis | 7 | 2019 | 4110 | 0.240 |
Why?
|
Gene Amplification | 3 | 2020 | 1088 | 0.240 |
Why?
|
Aspartate Aminotransferases | 2 | 2017 | 416 | 0.240 |
Why?
|
Retreatment | 2 | 2017 | 598 | 0.240 |
Why?
|
Follow-Up Studies | 12 | 2019 | 39117 | 0.240 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 2 | 2017 | 168 | 0.230 |
Why?
|
Immunohistochemistry | 6 | 2020 | 11073 | 0.230 |
Why?
|
Drug Delivery Systems | 2 | 2013 | 2225 | 0.230 |
Why?
|
Neoplasm Metastasis | 6 | 2022 | 4912 | 0.230 |
Why?
|
Intention to Treat Analysis | 3 | 2020 | 413 | 0.230 |
Why?
|
Receptor, trkB | 3 | 2019 | 124 | 0.230 |
Why?
|
Alanine Transaminase | 2 | 2017 | 603 | 0.220 |
Why?
|
Genotype | 8 | 2017 | 13009 | 0.220 |
Why?
|
Tomography, X-Ray Computed | 10 | 2019 | 20556 | 0.210 |
Why?
|
Disease Progression | 10 | 2020 | 13502 | 0.210 |
Why?
|
Animals | 26 | 2024 | 168441 | 0.200 |
Why?
|
Fibroblast Growth Factor 7 | 1 | 2021 | 59 | 0.190 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 243 | 0.190 |
Why?
|
Homeodomain Proteins | 1 | 2010 | 2416 | 0.190 |
Why?
|
Testosterone | 1 | 2012 | 2472 | 0.190 |
Why?
|
Lung | 5 | 2019 | 9995 | 0.190 |
Why?
|
Food-Drug Interactions | 1 | 2020 | 24 | 0.180 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2019 | 3602 | 0.180 |
Why?
|
Hepatocyte Growth Factor | 1 | 2021 | 270 | 0.170 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 4852 | 0.170 |
Why?
|
Oxidative Stress | 1 | 2011 | 3110 | 0.170 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2020 | 3639 | 0.170 |
Why?
|
Mice | 18 | 2024 | 81509 | 0.170 |
Why?
|
Phospholipase D | 1 | 2019 | 67 | 0.170 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2017 | 718 | 0.160 |
Why?
|
Radiosurgery | 3 | 2018 | 1342 | 0.160 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2019 | 198 | 0.160 |
Why?
|
Resorcinols | 1 | 2018 | 41 | 0.160 |
Why?
|
Pyridazines | 1 | 2020 | 202 | 0.160 |
Why?
|
Ethylnitrosourea | 1 | 2018 | 51 | 0.150 |
Why?
|
Aniline Compounds | 3 | 2018 | 1069 | 0.150 |
Why?
|
Amino Acid Substitution | 2 | 2021 | 1738 | 0.150 |
Why?
|
Carcinoma, Large Cell | 1 | 2018 | 113 | 0.150 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2017 | 332 | 0.150 |
Why?
|
Combined Modality Therapy | 4 | 2018 | 8529 | 0.150 |
Why?
|
Imidazoles | 2 | 2021 | 1180 | 0.140 |
Why?
|
Drug Discovery | 2 | 2016 | 1051 | 0.140 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2018 | 223 | 0.140 |
Why?
|
gamma-Glutamyltransferase | 1 | 2017 | 144 | 0.140 |
Why?
|
Isoxazoles | 1 | 2018 | 231 | 0.140 |
Why?
|
Platinum Compounds | 1 | 2017 | 95 | 0.140 |
Why?
|
Oncogene Fusion | 1 | 2017 | 81 | 0.140 |
Why?
|
Disease Models, Animal | 6 | 2019 | 18247 | 0.140 |
Why?
|
Transcription Factors | 2 | 2020 | 12125 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 9277 | 0.130 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 4575 | 0.130 |
Why?
|
Bone Morphogenetic Protein 3 | 1 | 2016 | 17 | 0.130 |
Why?
|
Genomics | 5 | 2023 | 5820 | 0.130 |
Why?
|
Genes, erbB-2 | 1 | 2017 | 162 | 0.130 |
Why?
|
Gene Order | 1 | 2016 | 169 | 0.130 |
Why?
|
Eligibility Determination | 1 | 2020 | 421 | 0.130 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2018 | 898 | 0.130 |
Why?
|
Protein Conformation | 2 | 2014 | 3969 | 0.130 |
Why?
|
Mutagenesis, Insertional | 1 | 2018 | 656 | 0.130 |
Why?
|
DNA, Neoplasm | 2 | 2018 | 1745 | 0.130 |
Why?
|
Mice, Nude | 4 | 2020 | 3614 | 0.130 |
Why?
|
Hyperlipidemias | 1 | 2020 | 771 | 0.130 |
Why?
|
Endpoint Determination | 2 | 2016 | 590 | 0.130 |
Why?
|
Peripartum Period | 1 | 2016 | 137 | 0.120 |
Why?
|
DNA Helicases | 1 | 2020 | 851 | 0.120 |
Why?
|
Thoracic Neoplasms | 1 | 2017 | 267 | 0.120 |
Why?
|
Organoplatinum Compounds | 1 | 2016 | 407 | 0.120 |
Why?
|
Family Characteristics | 1 | 2019 | 1003 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 350 | 0.120 |
Why?
|
Quality of Life | 6 | 2022 | 13361 | 0.120 |
Why?
|
Scleroderma, Localized | 1 | 2015 | 87 | 0.120 |
Why?
|
Cohort Studies | 6 | 2019 | 41446 | 0.110 |
Why?
|
Membrane Glycoproteins | 3 | 2019 | 3702 | 0.110 |
Why?
|
Benzoquinones | 1 | 2014 | 198 | 0.110 |
Why?
|
Exons | 2 | 2018 | 2393 | 0.110 |
Why?
|
Gene Knockout Techniques | 1 | 2017 | 802 | 0.110 |
Why?
|
Creatine Kinase | 1 | 2015 | 686 | 0.110 |
Why?
|
Arthritis, Experimental | 1 | 2016 | 291 | 0.110 |
Why?
|
Inhibitory Concentration 50 | 1 | 2014 | 465 | 0.110 |
Why?
|
Liver Failure | 1 | 2015 | 250 | 0.110 |
Why?
|
Kidney Diseases, Cystic | 1 | 2015 | 183 | 0.110 |
Why?
|
Time Factors | 5 | 2019 | 39975 | 0.110 |
Why?
|
Codon | 1 | 2015 | 602 | 0.110 |
Why?
|
Structure-Activity Relationship | 2 | 2021 | 3076 | 0.100 |
Why?
|
Gene Deletion | 1 | 2020 | 2667 | 0.100 |
Why?
|
Thymidylate Synthase | 1 | 2012 | 74 | 0.100 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2019 | 629 | 0.100 |
Why?
|
Administration, Oral | 3 | 2017 | 4016 | 0.100 |
Why?
|
Cell Proliferation | 4 | 2017 | 10441 | 0.100 |
Why?
|
Piperazines | 3 | 2019 | 2523 | 0.100 |
Why?
|
Language | 1 | 2021 | 1539 | 0.100 |
Why?
|
Internationality | 1 | 2017 | 1001 | 0.100 |
Why?
|
Alleles | 2 | 2021 | 6922 | 0.100 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1703 | 0.100 |
Why?
|
Edema | 1 | 2015 | 767 | 0.100 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 161 | 0.100 |
Why?
|
Oncogenes | 2 | 2016 | 1222 | 0.100 |
Why?
|
Neovascularization, Pathologic | 2 | 2015 | 2644 | 0.100 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 736 | 0.100 |
Why?
|
Enzyme Inhibitors | 3 | 2017 | 3712 | 0.090 |
Why?
|
Molecular Structure | 1 | 2015 | 1878 | 0.090 |
Why?
|
Immunoblotting | 2 | 2012 | 1647 | 0.090 |
Why?
|
Benzimidazoles | 2 | 2015 | 858 | 0.090 |
Why?
|
Enzyme Activation | 2 | 2014 | 3597 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1801 | 0.090 |
Why?
|
Constipation | 1 | 2015 | 562 | 0.090 |
Why?
|
Protein Stability | 1 | 2012 | 578 | 0.090 |
Why?
|
Osteoblasts | 1 | 2016 | 1143 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2021 | 3490 | 0.090 |
Why?
|
Cell Survival | 2 | 2019 | 5790 | 0.090 |
Why?
|
Membrane Proteins | 1 | 2007 | 7856 | 0.090 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2011 | 611 | 0.090 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2013 | 549 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6309 | 0.080 |
Why?
|
Blood-Brain Barrier | 1 | 2016 | 1027 | 0.080 |
Why?
|
Diagnostic Imaging | 2 | 2019 | 3530 | 0.080 |
Why?
|
Recombination, Genetic | 1 | 2014 | 1525 | 0.080 |
Why?
|
Models, Molecular | 2 | 2021 | 5439 | 0.080 |
Why?
|
Cancer Vaccines | 1 | 2016 | 1050 | 0.080 |
Why?
|
Prospective Studies | 6 | 2019 | 54415 | 0.080 |
Why?
|
Receptor, trkC | 2 | 2019 | 63 | 0.080 |
Why?
|
Cell Lineage | 1 | 2017 | 2555 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2507 | 0.080 |
Why?
|
Fatigue | 1 | 2015 | 1551 | 0.080 |
Why?
|
Hydroxychloroquine | 1 | 2012 | 426 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2013 | 1834 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2018 | 4021 | 0.080 |
Why?
|
Melanoma | 2 | 2017 | 5709 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 2455 | 0.080 |
Why?
|
Australia | 1 | 2011 | 1250 | 0.070 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2024 | 857 | 0.070 |
Why?
|
Microfluidics | 1 | 2013 | 653 | 0.070 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 2 | 2021 | 317 | 0.070 |
Why?
|
Triazoles | 1 | 2013 | 903 | 0.070 |
Why?
|
Fibroblasts | 2 | 2011 | 4140 | 0.070 |
Why?
|
Environment | 1 | 2013 | 1122 | 0.070 |
Why?
|
Cell Separation | 1 | 2013 | 1721 | 0.070 |
Why?
|
Embryo Loss | 1 | 2007 | 55 | 0.070 |
Why?
|
Genetic Markers | 1 | 2013 | 2613 | 0.070 |
Why?
|
Vision Disorders | 1 | 2014 | 1088 | 0.070 |
Why?
|
Binding Sites | 1 | 2015 | 6055 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1866 | 0.070 |
Why?
|
Recurrence | 1 | 2019 | 8469 | 0.070 |
Why?
|
RNA, Small Interfering | 2 | 2018 | 3428 | 0.070 |
Why?
|
DNA Primers | 1 | 2011 | 2820 | 0.070 |
Why?
|
Adolescent | 6 | 2019 | 88313 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 946 | 0.070 |
Why?
|
Thrombosis | 1 | 2020 | 2942 | 0.070 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 1334 | 0.060 |
Why?
|
Mice, SCID | 3 | 2018 | 2626 | 0.060 |
Why?
|
Tumor Cells, Cultured | 3 | 2020 | 6132 | 0.060 |
Why?
|
Cell Death | 1 | 2011 | 1677 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5794 | 0.060 |
Why?
|
Deglutition Disorders | 1 | 2011 | 625 | 0.060 |
Why?
|
Sirolimus | 1 | 2012 | 1533 | 0.060 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 1994 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2015 | 2047 | 0.060 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2007 | 3612 | 0.060 |
Why?
|
Signal Transduction | 5 | 2021 | 23441 | 0.060 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2021 | 1444 | 0.060 |
Why?
|
Cranial Irradiation | 2 | 2018 | 390 | 0.060 |
Why?
|
Uridine | 1 | 2023 | 141 | 0.050 |
Why?
|
Risk Assessment | 2 | 2017 | 23990 | 0.050 |
Why?
|
Glucuronosyltransferase | 1 | 2023 | 132 | 0.050 |
Why?
|
Reactive Oxygen Species | 1 | 2011 | 2141 | 0.050 |
Why?
|
Transfection | 1 | 2011 | 5775 | 0.050 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2024 | 517 | 0.050 |
Why?
|
Self Report | 1 | 2014 | 3724 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2023 | 2916 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 8999 | 0.050 |
Why?
|
Germ-Line Mutation | 2 | 2009 | 1858 | 0.050 |
Why?
|
Risk Factors | 4 | 2020 | 74167 | 0.050 |
Why?
|
Smoking | 1 | 2019 | 9052 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15838 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2016 | 12796 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2018 | 10203 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2011 | 5868 | 0.040 |
Why?
|
Pregnancy | 2 | 2016 | 29862 | 0.040 |
Why?
|
Apoptosis | 2 | 2019 | 9488 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2024 | 1062 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3874 | 0.040 |
Why?
|
Phosphorylation | 1 | 2011 | 8320 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2007 | 1486 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4320 | 0.040 |
Why?
|
Receptors, Growth Factor | 2 | 2010 | 326 | 0.040 |
Why?
|
Genetic Engineering | 1 | 2005 | 933 | 0.040 |
Why?
|
Drug Interactions | 1 | 2023 | 1414 | 0.040 |
Why?
|
Congenital Abnormalities | 1 | 2004 | 709 | 0.040 |
Why?
|
Triazines | 1 | 2021 | 311 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 612 | 0.040 |
Why?
|
Genetic Testing | 1 | 2011 | 3538 | 0.040 |
Why?
|
Keratin-8 | 1 | 2017 | 11 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2011 | 12970 | 0.040 |
Why?
|
Keratin-18 | 1 | 2017 | 38 | 0.040 |
Why?
|
Immunoprecipitation | 1 | 2020 | 878 | 0.040 |
Why?
|
INDEL Mutation | 1 | 2018 | 266 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5819 | 0.040 |
Why?
|
Neurofibromin 1 | 1 | 2018 | 190 | 0.040 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2020 | 373 | 0.040 |
Why?
|
Mice, Transgenic | 2 | 2007 | 9535 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6935 | 0.030 |
Why?
|
RNA | 1 | 2007 | 2723 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12456 | 0.030 |
Why?
|
Phthalazines | 1 | 2019 | 383 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2871 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2007 | 2898 | 0.030 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2016 | 89 | 0.030 |
Why?
|
Base Sequence | 1 | 2007 | 12450 | 0.030 |
Why?
|
Sex Factors | 1 | 2009 | 10548 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2011 | 18964 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15262 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 615 | 0.030 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2020 | 727 | 0.030 |
Why?
|
Cell Cycle Proteins | 2 | 2020 | 3447 | 0.030 |
Why?
|
Models, Biological | 1 | 2011 | 9469 | 0.030 |
Why?
|
Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 145 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2803 | 0.030 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 106 | 0.030 |
Why?
|
Quinazolinones | 1 | 2016 | 221 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2004 | 2824 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2021 | 1960 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2015 | 671 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1827 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 2469 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2020 | 2192 | 0.030 |
Why?
|
Dermatitis | 1 | 2015 | 201 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2020 | 1613 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1342 | 0.030 |
Why?
|
Age Factors | 1 | 2009 | 18400 | 0.030 |
Why?
|
Up-Regulation | 1 | 2021 | 4124 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2020 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2020 | 22163 | 0.030 |
Why?
|
Albumins | 1 | 2015 | 575 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 934 | 0.020 |
Why?
|
Cell Shape | 1 | 2013 | 371 | 0.020 |
Why?
|
Carboplatin | 1 | 2015 | 794 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2007 | 14409 | 0.020 |
Why?
|
Skull | 1 | 2016 | 818 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2018 | 1109 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1612 | 0.020 |
Why?
|
Cell Size | 1 | 2013 | 624 | 0.020 |
Why?
|
History, 21st Century | 1 | 2017 | 1567 | 0.020 |
Why?
|
Incidence | 2 | 2020 | 21341 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1090 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2013 | 750 | 0.020 |
Why?
|
Western World | 1 | 2009 | 27 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2020 | 0.020 |
Why?
|
Mass Screening | 1 | 2005 | 5428 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2015 | 1302 | 0.020 |
Why?
|
Drug Approval | 1 | 2016 | 814 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2009 | 270 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2012 | 2265 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5036 | 0.020 |
Why?
|
United States | 2 | 2018 | 72339 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2024 | 9179 | 0.020 |
Why?
|
Paclitaxel | 1 | 2015 | 1732 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3517 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2015 | 2914 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2024 | 10194 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8832 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 787 | 0.020 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 1021 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 1076 | 0.020 |
Why?
|
Gene Expression | 1 | 2017 | 7584 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2016 | 4354 | 0.010 |
Why?
|
Anticoagulants | 1 | 2020 | 4813 | 0.010 |
Why?
|
Genetics, Population | 1 | 2009 | 939 | 0.010 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2004 | 84 | 0.010 |
Why?
|
Pilot Projects | 1 | 2016 | 8633 | 0.010 |
Why?
|
Crosses, Genetic | 1 | 2004 | 750 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 6086 | 0.010 |
Why?
|
Genes, p53 | 1 | 2005 | 712 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2005 | 1750 | 0.010 |
Why?
|
Integrases | 1 | 2004 | 516 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2004 | 698 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6178 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2005 | 1784 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4172 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2018 | 36423 | 0.010 |
Why?
|
Embryo, Mammalian | 1 | 2004 | 1675 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 2005 | 1347 | 0.010 |
Why?
|
Viral Proteins | 1 | 2004 | 1803 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2005 | 3514 | 0.010 |
Why?
|
Cell Division | 1 | 2004 | 4466 | 0.010 |
Why?
|
Cell Cycle | 1 | 2004 | 2932 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2010 | 6485 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16606 | 0.010 |
Why?
|
Brain | 1 | 2018 | 27107 | 0.010 |
Why?
|
Stem Cells | 1 | 2004 | 3522 | 0.010 |
Why?
|
Child | 1 | 2018 | 80162 | 0.010 |
Why?
|